Michelson Diagnostics Achieves EU MDR Certification
Michelson Diagnostics, the leading provider of Optical Coherence Tomography (OCT) skin imaging systems, is proud to announce that it has been awarded CE Mark certification in Europe to MDR (Medical Device Regulation EU 2017/745) as a Class IIa medical device for its new VivoSight Dx Pro OCT system. MDR certification is recognised as one of ...
Societal benefits of faster skin cancer diagnosis highlighted
Optical Coherence Tomography, OCT, has the potential to speed and simplify diagnosis of Basal Cell Carcinoma Basal Cell Carcinoma, BCC, is the most common form of skin cancer and the most frequently occurring form of all cancers. Diagnosis of BCC usually involves the taking of a skin biopsy by a dermatologist, who will then send ...
Top-3 OCT Skin-Imaging publication topics in 2023
Optical Coherence Tomography, OCT, is being widely adopted for clinical, research and commercial skin-imaging applications As the leading dermatological OCT system VivoSight Dx has completed over 200,000 patient scans and has been used in over 500 peer-reviewed publications worldwide. During 2023 a total of 69 new peer-reviewed publications appeared featuring OCT imaging performed with VivoSight ...
Dermatological Optical Coherence Tomography (OCT) imaging available in Korea
Michelson Diagnostics is delighted to announce that it has received Korean Ministry of Food and Drug Safety, MFDS, (formerly the KFDA) approval for the VivoSight Dx Optical Coherence Tomography (OCT) system. VivoSight Dx is globally the most widely used OCT system for dermatological imaging, providing high-resolution, non-invasive images through the skin for a wide spectrum ...
Study finds Dynamic OCT can distinguish nevi and melanomas based on blood vessel morphology
The study, published in Cancers clinical journal, showed that VivoSight’s powerful Dynamic OCT (D-OCT) capability for detecting and imaging blood vessels in skin has the potential to help dermatologists non-invasively distinguish melanomas from suspicious nevi in unclear cases. According to the paper authors, adding D-OCT imaging to clinic-dermoscopic examination may: In the study, D-OCT images ...
Special Edition Q3, 2022
Feature 66% of Diagnostic Biopsies for Common Skin Cancer can be Avoided Using Michelson Diagnostics’ VivoSight OCT Laser Scanner Major Netherlands study shows that VivoSight OCT is non-inferior to and more cost-effective than punch biopsy This new publication in The Lancet Oncology reports results from the study performed in the Netherlands at three dermatology centres ...
March 2022
Latest News: Two Seminal Recent Articles Confirm Value of OCT for Basal Cell Carcinoma Authors identify the key OCT image characteristics and terminology for evidence-based, practical use in BCC management in clinical routine In the first article, published in JEADV by Fuchs et al.[1], a group of international OCT user experts agreed on a consensus ...
November 2021
Latest News: Early Success Indication of Lengthy Onychomycosis Treatment through OCT Biomarkers Potential for significant cost savings from high predictive value of OCT imaging biomarkers Feature: Mount Sinai Icahn School of Medicine Department of Dermatology Invests in Latest State-of-the-Art Skin Imaging Technologies VivoSight OCT part of a multi-technology approach for skin cancer and beyond “With ...
OCT-Guided Laser Treatment of Basal Cell Carcinoma
Jon Holmes, CEO of MDL, comments on a recent article by Orit Markowitz, MD et al. reporting positive results Join us for an educational video blog about an amazing new way treating Basal Cell Carcinoma. About Jon Holmes and Michelson Diagnostics Ltd. – Click Here.
